中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.017 seconds)

    Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
    1.
    发明申请
    Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent 审中-公开
    包含抗雌激素剂的乳腺癌组合疗法

    公开(公告)号：US20110124617A1

    公开(公告)日：2011-05-26

    申请号：US12991791

    申请日：2009-05-07

    Applicant: C. Richard Lyttle ,  Gary Hattersley ,  Louis O'Dea

    Inventor： C. Richard Lyttle ,  Gary Hattersley ,  Louis O'Dea

    IPC: A61K31/5685 ,  A61K31/138 ,  A61K31/4196 ,  A61P5/24 ,  A61P25/22

    CPC classification number: A61K45/06 ,  A61K31/137 ,  A61K31/138 ,  A61K31/4196 ,  A61K31/5685 ,  A61K2300/00

    Abstract: This invention relates to combination therapies for the treatment of breast cancer comprising administering to a subject in need thereof a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist, or an estrogen receptor downregulator) and to compositions (e.g., pharmaceutical compositions) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent. This invention also relates to a method of treating the side effects (e.g., vasomotor disturbances, osteoporosis and musculoskeletal complaints) associated with anti-estrogen therapy in a subject treated with one or more anti-estrogenic agents (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist or an estrogen receptor downregulator). The method comprises administering to the subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

    Abstract translation: 本发明涉及用于治疗乳腺癌的组合疗法，包括向有需要的受试者施用式I化合物或其药学上可接受的盐和抗雌激素药（例如芳香酶抑制剂，不是 式I的SERM，GNRH激动剂，GNRH拮抗剂或雌激素受体下调体）以及包含式I化合物或其药学上可接受的盐和抗雌激素剂的组合物（例如药物组合物）。 本发明还涉及一种治疗与一种或多种抗雌激素剂（例如，芳香酶抑制剂，SERM）治疗的受试者中与抗雌激素治疗相关的副作用（例如血管舒缩障碍，骨质疏松症和肌肉骨骼症） 不是式I的SERM，GNRH激动剂，GNRH拮抗剂或雌激素受体下调体）。 该方法包括向受试者施用有效量的式I化合物或其药学上可接受的盐。

    Isolated chemotactic factor from patients with endometriosis
    3.
    发明授权
    Isolated chemotactic factor from patients with endometriosis 失效
    子宫内膜异位症患者分离的趋化因子

    公开(公告)号：US5877284A

    公开(公告)日：1999-03-02

    申请号：US460326

    申请日：1995-06-02

    Applicant: C. Richard Lyttle

    Inventor： C. Richard Lyttle

    IPC: C07K14/52 ,  C07K14/435

    CPC classification number: C07K14/52 ,  Y10S435/81

    Abstract: A composition comprising a soluble peptide of about 23 kD to about 29 kD, capable of causing neutrophil and macrophage chemotaxis, and which is substantially similar to chemotactic factor from peritoneal fluid of mammals with minimal or moderate endometriosis.

    Abstract translation: 一种组合物，其包含约23kD至约29kD的可溶性肽，其能够引起嗜中性粒细胞和巨噬细胞趋化性，并且其基本上类似于具有最小或中度子宫内膜异位症的哺乳动物腹膜液的趋化因子。

    METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN
    10.
    发明申请
    METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN 有权
    骨质疏松蛋白药物递送方法

    公开(公告)号：US20130157955A1

    公开(公告)日：2013-06-20

    申请号：US13438086

    申请日：2012-04-03

    Applicant: Michael J. Dey ,  Nathalie Mondoly ,  Benedicte Rigaud ,  Bart Henderson ,  C. Richard Lyttle

    Inventor： Michael J. Dey ,  Nathalie Mondoly ,  Benedicte Rigaud ,  Bart Henderson ,  C. Richard Lyttle

    IPC: A61K38/29

    CPC classification number: A61K38/29 ,  A61K9/0019 ,  A61K9/08

    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.

    Abstract translation: 本发明提供含有甲状旁腺激素相关蛋白（PTHrP）的储存稳定组合物和使用本文所述的PTHrP和PTHrP组合物治疗骨质疏松症，增加骨质量或增加骨质量的方法。 该组合物是储存稳定的，为无菌形式，并且通常可以在室温下储存至少数周，以方便肠胃外给予人类患者。

Patent Agency Ranking